Protocol Specific Research Support (PSRS)

协议特定研究 协议特定研究计划提供数据管理和其他基础设施支持 由基梅尔癌症中心成员设计和实施的新临床试验。这些审判是 创新的早期阶段(I或II)和/或试点研究，测试可能导致扩展的概念， 外部资助的研究。自从上一次拨款申请以来，坎摩尔癌症中心的调查人员 一直致力于开发由调查员发起的试验。机构基金覆盖经验丰富的人 这些试验的支持人员。正在申请资金，为更多的临床工作提供财政支持 计划中的调查员发起试验(IIT)的研究协调员。最受重视的领域有 一直在开发创新的“第一人”试验的新药物，与治疗 辐射。这些试验是在多学科领导下进行的，包括放射肿瘤学家， 内科肿瘤学家、外科肿瘤学家和翻译科学家。在过去的6年里， 这些试验从3项增加到9项现行试验。目前开放的9个多模式IIT占60% 癌症中心在2006年的治疗收益。截至2007年4月，共有3个多模式IIT试验 正在积极发展中。该机构将继续为支持这些IIT试验的工作人员提供资金。

PROTOCOL SPECIFIC RESEARCH The Protocol Specific Research program provides data management and other infrastructure support of novel clinical trials designed and implemented by Kimmel Cancer Center members. These trials are innovative, early phase (I or II), and/or pilot studies testing concepts that are likely to lead to expanded, externally funded studies. Since the last grant submission, the investigators at the Kimmel Cancer Center have been committed to the development of investigator-initiated trials. Institutional funds cover experienced support staff for these trials. Funds are being requested to provide financial support for additional clinical research coordinators for the planned investigator initiated trials (IIT). The area of greatest emphasis has been in the development of innovative "first-in-man" trials of new agents, in conjunction with therapeutic radiation. These trials are conducted with multi-disciplinary leadership including radiation oncologists, medical oncologists, surgical oncologists, and translational scientists. Over the last 6 years, the number of these trials has increased from 3 to 9 active trials. The 9 multi-modality IIT currently open accounted for 60% of the cancer center therapeutic accrual during 2006. As of April, 2007, there are 3 multi-modality IIT trials under active development. The institution will continue to provide funds to support staff for these IIT trials.